Allergy is a complex immune phenomenon responsible for a wide range of undesirable reactions to various stimuli. For example, a significant proportion of atopic dermatitis cases (which are responsible for approximately 10% of vet visits) are related to allergies.

Informed by supportive late-stage human data, Nexvet is researching several as-yet undisclosed biologic targets with potential efficacy in canine and feline allergic conditions.

The treatment of atopic dermatitis in dogs 

Atopic dermatitis is one of a number of chronic inflammatory diseases that affect a variety of organ systems in dogs and cats, similar to the effects seen in humans. Other examples include arthritis, inflammatory bowel disease, type 1 diabetes and cardiovascular disease.

Canine atopic dermatitis is a common condition in dogs of all ages, affecting approximately 10% of all dogs. Dogs with atopic dermatitis display skin lesions with itching that often lead to further damage and infection which exacerbates their symptoms.

Atopic dermatitis is currently treated with various approaches, including dietary supplements, topical shampoos, emollients and ointments, anti-histamines, NSAIDs, and immunosuppressant drugs such as oral steroids and ATOPICA®. This latter class of drug can have serious side effects such as vomiting, diarrhea, and an increased risk of cancers.

Nexvet Biopharma

Unit 5, Sragh Technology Park
Rahan Road, Tullamore
Co. Offaly, R35 FR98
P: + 353 5793 24522 

Level 8, 31 Queen Street
Melbourne 3000
P: +61 (3) 9610 4400

Get in Touch